Published online before print February 26, 2009

This Article Full Text Full Text (PDF) All Versions of this Article: ajpath.2009.080958v1 174/4/1149    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watanabe, T. Articles by Ohgaki, H. Search for Related Content PubMed PubMed Citation Articles by Watanabe, T. Articles by Ohgaki, H.

(American Journal of Pathology. 2009;174:1149-1153.)
© 2009 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2009.080958

Short Communications

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

Takuya Watanabe^*, Sumihito Nobusawa^*, Paul Kleihues and Hiroko Ohgaki^*

From the International Agency for Research on Cancer,^* Lyon, France; and the Department of Pathology, University Hospital Zurich, Zurich, Switzerland

IDH1 encodes isocitrate dehydrogenase 1, which participates in the citric acid cycle and was recently reported to be mutated in 12% of glioblastomas. We assessed IDH1 mutations in 321 gliomas of various histological types and biological behaviors. A total of 130 IDH1 mutations was detected, and all were located at amino acid residue 132. Of these, 91% were GA mutations (ArgHis). IDH1 mutations were frequent in low-grade diffuse astrocytomas (88%) and in secondary glioblastomas that developed through progression from low-grade diffuse or anaplastic astrocytoma (82%). Similarly, high frequencies of IDH1 mutations were found in oligodendrogliomas (79%) and oligoastrocytomas (94%). Analyses of multiple biopsies from the same patient (51 cases) showed that there were no cases in which an IDH1 mutation occurred after the acquisition of either a TP53 mutation or loss of 1p/19q, suggesting that IDH1 mutations are very early events in gliomagenesis and may affect a common glial precursor cell population. IDH1 mutations were co-present with TP53 mutations in 63% of low-grade diffuse astrocytomas and with loss of heterozygosity 1p/19q in 64% of oligodendrogliomas; they were rare in pilocytic astrocytomas (10%) and primary glioblastomas (5%) and absent in ependymomas. The frequent presence of IDH1 mutations in secondary glioblastomas and their near-complete absence in primary glioblastomas reinforce the concept that despite their histological similarities, these subtypes are genetically and clinically distinct entities.

This article has been cited by other articles:

				S. Gross, R. A. Cairns, M. D. Minden, E. M. Driggers, M. A. Bittinger, H. G. Jang, M. Sasaki, S. Jin, D. P. Schenkein, S. M. Su, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations J. Exp. Med., February 8, 2010; (2010) jem.20092506v1. [Abstract] [Full Text] [PDF]

				H. Yan, D. D. Bigner, V. Velculescu, and D. W. Parsons Mutant Metabolic Enzymes Are at the Origin of Gliomas Cancer Res., December 15, 2009; 69(24): 9157 - 9159. [Abstract] [Full Text] [PDF]

				S. Nobusawa, T. Watanabe, P. Kleihues, and H. Ohgaki IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas Clin. Cancer Res., October 1, 2009; 15(19): 6002 - 6007. [Abstract] [Full Text] [PDF]

				H. Carter, S. Chen, L. Isik, S. Tyekucheva, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, and R. Karchin Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations Cancer Res., August 15, 2009; 69(16): 6660 - 6667. [Abstract] [Full Text] [PDF]

				E. De Carli, X. Wang, S. Puget, F. Ducray, Y. Marie, M. Sanson, Z. Reitman, and H. Yan IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med., May 21, 2009; 360(21): 2248 - 2248. [Full Text] [PDF]